Ancora Microcap Fund
Objective & Share Information
The Ancora Microcap Fund’s primary objective is capital appreciation.
|Symbol||Share Class||Expense Ratio*||Minimum*||Maximum Sales Charge|
* The Advisor and the Trust have entered into a fee waiver agreement whereby the Advisor has contractually agreed to waive a portion of its fees in order to limit total annual fund operating expenses (excluding Fees and Expenses of Acquired Funds and certain other items) to 1.60% for Class I shares. These fee waivers will remain in effect until at least April 30, 2016 but can be terminated by a vote of the Board of Trustees of the Fund if they deem the termination to be beneficial to the Fund shareholders. The Advisor is entitled to recover such waived amounts within the same fiscal year in which the Advisor reduced its fee. No recoupment will occur except to the extent that the Fund’s expenses, together with the amount recovered, do not exceed the applicable expense limitation. The gross expense ratio of the Class I shares would have been 1.79% without the Advisor’s waiver. See prospectus for additional expense ratio detail and minimum purchase eligibility requirements.
Philosophy & Process
Performance as of 6/30/15
|Q2||YTD||1 Yr.||3 Yrs.||5 Yrs.||Since Incep. (09/01/08)|
|Ancora Microcap Fund (ANCIX)||1.63%||1.48%||11.71%||19.37%||15.99%||11.75%|
|Ancora Microcap Fund (ANCCX)||1.42%||1.12%||10.81%||18.37%||15.17%||11.04%|
|Russell Microcap Index||2.80%||6.03%||8.23%||19.26%||17.49%||8.86%|
Performance quoted represents past performance and is not a guarantee or a reliable indicator of future results. Investment return and the principal value of an investment will fluctuate. Shares may be worth more or less than original cost when redeemed. Current performance may be lower or higher than average annual returns shown. A Redemption Fee of 2% may be assessed on shares held less than 90 days. The performance data presented does not reflect the deduction of this fee and if reflected would reduce the performance returns.
Top Ten Holdings as of 6/30/15
|1||Lakeland Industries, Inc.||LAKE||3.76%|
|2||Jakks Pacific, Inc.||JAKK||2.35%|
|4||Albany Molecular Research, Inc.||AMRI||2.26%|
|5||Harris & Harris Group, Inc.||TINY||2.23%|
|6||Axcelis Technologies, Inc.||ACLS||2.23%|
|8||MVC Capital, Inc.||MVC||2.16%|
|9||Sanfilippo John B & Son Inc.||JBSS||1.90%|
|10||Callaway Golf Co,||ELY||1.87%|
- Direct Application (click here)
- Pershing LLC
- Charles Schwab
- TD Ameritrade
- National Financial Services
Additional Purchase Information: Dan Hyland, Managing Director, Marketing & Client Services email@example.com, 216-825-4000
General Risk Disclosures
Investors should consider the investment objectives, risks, charges and expenses of the funds carefully before investing. This and other information are contained in the fund’s prospectus and summary prospectus, if available, which may be obtained by contacting your Ancora representative, financial advisor or by clicking here.
Ancora Microcap Fund Risk Disclosures
Speculative Nature. The Fund intends to invest in securities that are more speculative than other securities and, therefore, subject to a substantial decline or total loss in value. Because of the speculative nature of these securities, shareholders of the Fund are exposed to a high degree of risk.
Micro Cap Companies. The principal risks of investing in the Fund include the risks of investing in equity securities. The prices of equity securities fluctuate based on changes in a company’s activities and financial condition and in overall market and financial conditions. The micro cap companies in which the Fund invests are especially sensitive to these factors and therefore may be subject to greater share price fluctuations than other companies. Also, securities of these companies are often less liquid, thus possibly limiting the ability of the Fund to dispose of such securities when the Advisor deems it advisable to do so. As a result of these factors, securities of these micro cap companies may expose shareholders of the Fund to above average risk.